11 August 2017 - Onivyde, in combination with 5-fluorouracil and leucovorin, is the first and only treatment shown to increase median overall survival by up to two months for adult pancreatic cancer patients who have disease progression following gemcitabine-based therapy.

Shire Canada today announced that Onivyde (irinotecan liposome for injection) has been approved for the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil and leucovorin, in adult patients who have disease progression following gemcitabine-based therapy.

Onivyde is the first and only approved treatment option for this patient population who have no universally accepted standard of treatment until now. Based on the NAPOLI-1 trial, Onivyde has been shown to extend patients' overall survival by two additional months.

Read Shire Canada press release